Associations between Polymorphisms in the vitamin D receptor and breast cancer risk

被引:101
作者
Chen, WY
Bertone-Johnson, ER
Hunter, DJ
Willett, WC
Hankinson, SE
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Publ Hlth, Dept Med,Channing Lab, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[5] Univ Massachusetts, Dept Publ Hlth, Amherst, MA 01003 USA
关键词
D O I
10.1158/1055-9965.EPI-05-0283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biological and epidemiologic data suggest that vitamin D levels may influence breast cancer development. The vitamin D receptor (VDR) is a crucial mediator for the cellular effects of vitamin D and additionally interacts with other cell-signaling pathways that influence cancer development. Because functional data exist on FOK1 and previous studies have suggested a relation between BSM1 and breast cancer risk, we evaluated the associations of the FOK1 and BSM1 VDR polymorphisms and breast cancer risk. In a case-control study nested within the Nurses' Health Study, we genotyped 1,234 incident cases (diagnosed between return of a blood sample in 1989-1990 and June 1, 2000) and 1,676 controls for FOK1, and 1,180 cases and 1,547 controls for BSM1. We observed a significantly increased risk of breast cancer among carriers of the ff genotype of FOK1 (multivariate odds ratio, 1.34; 95% confidence intervals, 1.06-1.69) compared with those with FF. We did not observe an association between polymorphisms in BSM1 and breast cancer risk (multivariate odds ratio, 0.93; 95% confidence intervals, 0.72-1.20) for BB versus bb). The FOK1 association did not vary significantly by menopausal status, estrogen, and progesterone receptor status of the tumors, or plasma levels of 25 hydroxyvitamin D or 1,25 dihydroxyvitamin D. Our results suggest that the VDR may be a mediator of breast cancer risk and could represent a target for cancer prevention efforts.
引用
收藏
页码:2335 / 2339
页数:5
相关论文
共 41 条
  • [1] A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women
    Arai, H
    Miyamoto, KI
    Taketani, Y
    Yamamoto, H
    Iemori, Y
    Morita, K
    Tonai, T
    Nishisho, T
    Mori, S
    Takeda, E
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (06) : 915 - 921
  • [2] IMMUNOCYTOCHEMICAL DETECTION OF 1,25-DIHYDROXYVITAMIN-D RECEPTORS IN NORMAL HUMAN-TISSUES
    BERGER, U
    WILSON, P
    MCCLELLAND, RA
    COLSTON, K
    HAUSSLER, MR
    PIKE, JW
    COOMBES, RC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (03) : 607 - 613
  • [3] BERGER U, 1991, CANCER RES, V51, P239
  • [4] Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer
    Bertone-Johnson, ER
    Chen, WY
    Holick, MF
    Hollis, BW
    Colditz, GA
    Willett, WC
    Hankinson, SE
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (08) : 1991 - 1997
  • [5] Bone mineral density and risk of breast cancer in older women - The study of osteoporotic fractures
    Cauley, JA
    Lucas, FL
    Kuller, LH
    Vogt, MT
    Browner, WS
    Cummings, SR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17): : 1404 - 1408
  • [6] METHODS FOR THE DETERMINATION OF THE CIRCULATING CONCENTRATION OF 25-HYDROXYVITAMIN-D
    CHEN, TC
    TURNER, AK
    HOLICK, MF
    [J]. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 1990, 1 (06) : 315 - 319
  • [7] Association of the vitamin D receptor start codon polymorphism (FokI) with bone mineral density in postmenopausal Korean women
    Choi, YM
    Jun, JK
    Choe, J
    Hwang, D
    Park, SH
    Ku, SY
    Kang, D
    Kim, JG
    Moon, SY
    Lee, JY
    [J]. JOURNAL OF HUMAN GENETICS, 2000, 45 (05) : 280 - 283
  • [8] Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25-dihydroxyvitamin D3
    Colin, EM
    Weel, AEAM
    Uitterlinden, AG
    Buurman, CJ
    Birkenhäger, JC
    Pols, HAP
    van Leeuwen, JPTM
    van Leeuwen,
    [J]. CLINICAL ENDOCRINOLOGY, 2000, 52 (02) : 211 - 216
  • [9] COLSTON KW, 1989, LANCET, V1, P188
  • [10] EFFECTS OF SYNTHETIC VITAMIN-D ANALOGS ON BREAST-CANCER CELL-PROLIFERATION INVIVO AND INVITRO
    COLSTON, KW
    CHANDER, SK
    MACKAY, AG
    COOMBES, RC
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 44 (04) : 693 - 702